SLIT Risks: A Balanced Look at Sublingual Immunotherapy

The most common risk of sublingual immunotherapy is also the least serious: local reactions in and around the mouth, such as itching under the tongue, throat irritation, ear itching, and minor lip or tongue swelling. A 2024 meta-analysis found these affect roughly 40.8 percent of patients. They typically start within minutes of dosing, settle quickly, and ease over the first few weeks as the mouth adapts. A smaller number of people report mild nausea or other gastrointestinal effects. These common risks are generally mild and self-limiting, which is why most SLIT dosing happens at home after a supervised first dose. The rarer, more serious risks, systemic reactions and anaphylaxis, are far less frequent.

The risk of a serious reaction with sublingual immunotherapy is low. Systemic reactions, meaning symptoms beyond the mouth such as widespread hives or wheezing, occur in about 1.1 percent of patients and are usually mild. Anaphylaxis is exceptionally rare, estimated near 1 per 100 million doses, and no SLIT fatality has been reported worldwide. So while serious reactions are possible, life-threatening ones are exceptionally uncommon. Practical safeguards reflect this: providers often supervise the first dose and may prescribe an epinephrine auto-injector, and candidates with uncontrolled or severe asthma are excluded because asthma raises the stakes of a systemic reaction.

Eosinophilic esophagitis, often abbreviated EoE, is a recognized but rare risk associated with sublingual immunotherapy, and it is important enough that it is considered a contraindication. EoE is an inflammatory condition of the esophagus driven by an accumulation of eosinophils, and it typically presents as progressively worsening difficulty swallowing or a sensation of food sticking in the chest. The association appears to relate to the swallowed portion of the allergen extract. Because it is a contraindication, people with known EoE generally should not start sublingual immunotherapy, and anyone who develops persistent swallowing difficulty during treatment should stop and contact their provider for evaluation, which may involve a referral to gastroenterology. While EoE is uncommon, it is worth knowing about before starting any sublingual immunotherapy program, since recognizing the symptoms early allows for prompt assessment and, if needed, discontinuation of treatment.

Asthma is directly relevant to SLIT risk, which is why providers screen for it before treatment. Uncontrolled or severe asthma is a contraindication, because poorly controlled airways increase the potential severity of a systemic reaction. The key distinction is control: well-managed asthma is generally not a barrier to sublingual immunotherapy, while uncontrolled asthma is. Getting good asthma control is a prerequisite before starting, and your provider may assess your breathing as part of the evaluation. In short, asthma raises SLIT risk only when it isn't well controlled, so be candid with your provider about any breathing problems.

The risk profiles differ mainly in systemic reactions. Sublingual immunotherapy carries a lower risk of systemic reactions than allergy shots, because the allergen stays in contact with the oral lining rather than being injected into tissue. Systemic reactions occur in about 1.1 percent of SLIT patients, and no SLIT fatality has been reported worldwide, whereas injected immunotherapy is linked to a higher systemic-reaction rate. In exchange, SLIT brings a more frequent but milder burden of local oral reactions, while shots more often cause injection-site reactions. This is a difference in risk profile, not a sign that shots are unsafe.

Odactra is an FDA-approved house dust mite SLIT tablet, and its side-effect pattern follows what's reported for sublingual immunotherapy generally: mild, local, mouth-area reactions are most common, including itching under the tongue, throat irritation, and mouth or lip swelling. Less often, people report nausea or stomach upset. Serious systemic reactions and anaphylaxis are rare, but Odactra's label carries a warning about eosinophilic esophagitis and advises having an epinephrine auto-injector available, with the first dose taken under medical supervision. Check Odactra's FDA label or ask your prescriber for its full side-effect list.